NPM1 and acute myeloid leukemia: As a result, the impact of NPM1, FLT3-ITD and CEBPA mutations was further defined based on the presence of other mutations such as RUNX1, ASXL1 and TP53. This has advanced prognosis and therapeutic options in AML.